ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1674

eNOS/NO Signaling Attenuates Progression of Age-Related Kidney Diseases via Suppression of Inflammasome

Session Information

Category: Geriatric Nephrology

  • 1100 Geriatric Nephrology

Authors

  • Nagasu, Hajime, Kawasaki Medical School, Kurashiki, Okayama, Japan
  • Wada, Yoshihisa, Kawasaki Medical School, Kurashiki, Okayama, Japan
  • Kadoya, Hiroyuki, Kawasaki Medical School, Kurashiki, Okayama, Japan
  • Kondo, Megumi, Kawasaki Medical School, Kurashiki, Okayama, Japan
  • Kidokoro, Kengo, Kawasaki Medical School, Kurashiki, Okayama, Japan
  • Kanda, Eiichiro, Kawasaki Medical School, Kurashiki, Okayama, Japan
  • Kishi, Seiji, Kawasaki Medical School, Kurashiki, Okayama, Japan
  • Sasaki, Tamaki, Kawasaki Medical School, Kurashiki, Okayama, Japan
  • Kashihara, Naoki, Kawasaki Medical School, Kurashiki, Okayama, Japan
Background

Ageing affects the function of the immune system and leads to immunosenescence, which is characterized by defective immune responses and increased systemic inflammation (also termed inflammageing). Inflammageing is maladaptive and results from multiple mechanisms, including aberrant inflammasome activation. The ASC is an essential component of inflammasome. Endothelial dysfunction is also a common pathophysiologic mechanism of age-related organ damage. Nitric oxide (NO) produced by endothelial nitric oxide synthase (eNOS) is an important mediator in the maintenance of vascular homeostasis. We've reported that the eNOS-NO pathway attenuates the progression of kidney injury via suppression of inflammasomes. However, the relationship between the eNOS-NO pathway and inflammageing in the kidney remains unclear. To determine if the eNOS-NO pathway attenuates kidney damage via the regulation of inflammasome in ageing kidney, we used eNOS-deficient mice (eNOSKO) and eNOS-ASC double-knockout mice (eNOS-ASC-DKO).

Methods

Wild-type mice (WT) and eNOSKO were used to determine the role of the eNOS-NO pathway in ageing kidneys. WT and eNOSKO were sacrificed at 18 months of age to harvest kidney tissue. The localization of inflammasome activation in the kidney was evaluated with immunohistochemical analyses. To determine the role of inflammasomes in ageing kidneys, we generated eNOS-ASC-DKO. The mRNA expression of inflammasome components were determined in isolated glomeruli.

Results

The glomerular injury was more exacerbated in eNOSKO-18M than in WT-18M. In the immunohistochemical, the expression of ASC coexisted with the macrophages detected by F4/80 staining in eNOSKO-18M. These data suggested that the inflammasome activation was located in the macrophages.In the isolated glomeruli, mRNA of inflammasome components were higher in eNOSKO-18M than in WT-18M. The glomerular damage were ameliorated in eNOS-ASC-DKO-18M compared to eNOSKO-18M. In summary, in eNOSKO, inflammasomes were activated in macrophages, and interstitial fibrosis was exacerbated. However, in eNOS-ASC-DKO-18M mice, the tubulointerstitial damage was attenuated.

Conclusion

Endothelial NOS/NO signaling ameliorates kidney damage in the aging process via the modulation of inflammageing associated with inflammasome-activation.